Platelet-Rich Plasma Policy
Defines medical necessity and coverage for platelet-rich plasma (PRP) therapies across Independent Health lines of business (Commercial, Self-Funded, Medicare Advantage, and State products) including place-of-service limitations and Medicare policy references. Describes noncoverage as experimental/investigational for most indications and coverage for certain state plan settings.
Reviewed on 7/1/2025 with revised formatting only.
Coverage Summary
Independent Health policy M20130117011 (effective 2013-04-01; last reviewed 2025-07-01) takes a mixed coverage stance across lines of business. For Commercial and Self-Funded plans PRP and platelet-derived growth factors are considered experimental/investigational for all indications (not covered). Medicare Advantage follows the Commercial criteria except where CMS determinations apply (see CMS LCD/LCA and NCD references). For State products (MediSource, MediSource Connect, Child Health Plus, Essential Plan) PRP is a covered benefit only when performed in specified Article 28 places of service and is not covered in Article 11 provider offices. Preauthorization is required where applicable.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.